Foye's Principles of Medicinal ChemistryThomas L. Lemke, David A. Williams Lippincott Williams & Wilkins, 2008 - 1377 sivua The Sixth Edition of this well-known text has been fully revised and updated to meet the changing curricula of medicinal chemistry courses. Emphasis is on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems. Also new to this edition: Clinical Significance boxes, Drug Lists at the beginning of appropriate chapters, and an eight-page color insert with detailed illustrations of drug structures. Case studies from previous editions and answers to this edition's case studies are available online at thePoint. |
Sisältö
Historical Perspective of Medicinal Chemistry | 1 |
Drug Discovery from Natural Products | 12 |
Chapter | 25 |
Drug Design and Relationship | 26 |
Chapter 3 | 53 |
Receptors and Drug Action | 87 |
Drug Discovery Through Enzyme | 99 |
Pharmaceutical Biotechnology | 115 |
Chapter 20 | 513 |
Chapter 21 | 547 |
Opioid Analgesics | 652 |
Drugs Used to Treat Neuromuscular | 679 |
Drugs Affecting the Cardiovascular System | 698 |
Chapter 27 | 722 |
AngiotensinConverting Enzyme | 738 |
Antihyperlipoproteinemics and Inhibitors | 799 |
Chapter 8 | 143 |
Chapter 9 | 151 |
Physicochemical and Biopharmaceutical | 210 |
Drug Metabolism | 253 |
Chapter 11 | 327 |
DRUG RECEPTORS AFFECTING | 339 |
Chapter 12 | 361 |
Adrenergic Receptors and Drugs Affecting | 392 |
Phosphodiesterase Inhibitors | 480 |
PHARMACODYNAMIC AGENTS | 487 |
SedativeHypnotics | 504 |
Antithrombotics Thrombolytics | 820 |
Antiparasitic Agents | 1084 |
Antifungal Agents | 1112 |
Chapter 41 | 1127 |
Drugs Affecting the Hormonal Systems | 1142 |
Chapter 43 | 1193 |
Chapter 33 | 1219 |
Chapter 35 | 1230 |
ZAVOD | 1301 |
Appendix | 1354 |
Muita painoksia - Näytä kaikki
Foye's Principles of Medicinal Chemistry Thomas L. Lemke,David A. Williams Esikatselu ei käytettävissä - 2008 |
Yleiset termit ja lausekkeet
5-HT receptors absorption acetylcholine action activity administration affinity agents agonists amine amino acid anesthetic antagonists antidepressants antisense aromatic atoms barbiturates benzodiazepines binding bioavailability biological bond cell CH3 CH3 Chem chemical chemistry clinical compounds conjugation decrease depression disease dose drug discovery effects elimination enantiomers enzyme ester excreted factors functional groups G protein-coupled receptors GABA gene genetic glucuronide H₂N half-life hepatic hepatotoxicity hormone human hydrolysis hydroxylation increase inhibition inhibitors interactions intestinal ion channels isoforms ligand lipid liver local anesthetics mechanism membrane metabolites molecular molecule muscarinic neurons neurotransmitter nicotinic norepinephrine oral oxidation P-gp pathway patients peptide pharmaceutical pharmacokinetics Pharmacol pharmacological pharmacophore phenobarbital phenytoin plasma concentration potential properties protein protein-coupled reactions reactive residues response result seizures selective sequence serotonin sleep sodium solubility specific structure studies substrate subunit synthesis target therapeutic therapy tion tissue toxicity treatment U.S. FDA urine xenobiotics